Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.38 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23509414 | 0.84 | PIK3CD (0.39) | MEN1ALDH1A1KMT2AEPHX2CYP2D6 | |
| SCHEMBL23842279 | 0.79 | EPHX2 (0.43) | ALDH1A1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL23945967 | 0.79 | ALDH1A1 (0.33) | ALDH1A1EPHX2 | |
| SCHEMBL23509502 | 0.79 | — | — | |
| SCHEMBL23105073 | 0.78 | POLB (0.45) | MEN1ALDH1A1KMT2AEPHX2CYP2C9 | |
| SCHEMBL23710960 | 0.78 | CPN1 (0.44) | ALDH1A1 | |
| SCHEMBL19652203 | 0.78 | MEN1 (0.43) | MEN1ALDH1A1KMT2ACHRNB2CHRNA3 | |
| SCHEMBL22525774 | 0.77 | ALDH1A1 (0.34) | MEN1ALDH1A1KMT2AEPHX2 | |
| SCHEMBL12376562 | 0.76 | HPGD (0.49) | ALDH1A1HRH3L3MBTL1 | |
| SCHEMBL24233080 | 0.72 | HRH3 (0.34) | CYP2D6KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | MEN1 2268/4885ALDH1A1 1804/4885KMT2A 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.